For TGFB2-dependent biomarkers, elevated TGFB2 mRNA expression is a prognostic biomarker associated with breast cancer patients that is correlated with improved OS outcomes at high expression levels of GDAP1, TBL1XR1, RNFT1, HACL1, SLC27A2, NLE1, and TXNDC16. This evidence concerns the gene NLE1 and breast carcinoma.